Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1-3/2007

01-11-2007

Cytokine signaling to the cell cycle

Author: Frederick W. Quelle

Published in: Immunologic Research | Issue 1-3/2007

Login to get access

Abstract

The proliferation of many myeloid and lymphoid cell populations is directly controlled by cytokine growth factors acting through a related family of cytokine receptors. This regulation implies that the signaling pathways activated by cytokine receptors must communicate with mechanisms that control mammalian cell cycle progression. Evidence for how these signaling pathways promote hematopoietic cell proliferation is considered along with their likely targets among the cell cycle regulators.
Literature
1.
von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995;181:1519–26.
2.
Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994;180:1955–60.PubMed
3.
Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147–57.PubMed
4.
Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800–2.PubMed
5.
Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794–7.PubMed
6.
Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991;254:707–10.PubMed
7.
Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996;4:471–81.PubMed
8.
Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995;83:59–67.PubMed
9.
Lin CS, Lim SK, D’Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996;10:154–64.PubMed
10.
Nishinakamura R, Miyajima A, Mee PJ, Tybulewicz VL, Murray R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony- stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996;88:2458–64.PubMed
11.
Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN, et al. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 1998;12:1099–107.PubMed
12.
Eapen AK, Henry MK, Quelle DE, Quelle FW. DNA damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol Cell Biol 2001;21:6113–21.PubMed
13.
Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev 2001;101:2511–26.PubMed
14.
Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630–41.PubMed
15.
Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393–409.PubMed
16.
Kaldis P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol Life Sci 1999;55:284–96.PubMed
17.
Nagahara H, Ezhevsky SA, Vocero-Akbani AM, Kaldis P, Solomon MJ, Dowdy SF. Transforming growth factor beta targeted inactivation of cyclin E: cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci 1999;96:14961–6.PubMed
18.
Chiariello M, Gomez E, Gutkind JS. Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G(1) phase. Biochem J 2000;349:869–76.PubMed
19.
Kaldis P, Solomon MJ. Analysis of CAK activities from human cells. Eur J Biochem 2000;267:4213–21.PubMed
20.
Leclerc V, Raisin S, Leopold P. Dominant-negative mutants reveal a role for the Cdk7 kinase at the mid-blastula transition in Drosophila embryos. EMBO J 2000;19:1567–75.PubMed
21.
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–12.PubMed
22.
Ekholm SV, Reed SI. Regulation of G(1) cyclin dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676–84.PubMed
23.
Stepanova L, Sorrentino BP. A limited role for p16(Ink4a) and p19(Arf) in the loss of hematopoietic stem cells during proliferative stress. Blood 2005;106:827–32.PubMed
24.
Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16(INK4a). Nature 2006;443:421–6.PubMed
25.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153–60.PubMed
26.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145–52.PubMed
27.
Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136–44.PubMed
28.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682–5.PubMed
29.
Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999;274:13886–93.PubMed
30.
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181–9.PubMed
31.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707–20.PubMed
32.
Kiyokawa H, Kineman RD, ManovaTodorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721–32.PubMed
33.
Ando K, Ajchenbaum-Cymbalista F, Griffin JD. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci 1993;90:9571–5.PubMed
34.
Kato JY, Sherr CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci 1993;90:11513–7.PubMed
35.
Leonard WJ, Lin JX. Cytokine receptor signaling pathways. J Allergy Clin Immunol 2000;105:877–88.PubMed
36.
Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al. Signaling by Type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001;13:363–73.PubMed
37.
Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797–800.PubMed
38.
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309–12.PubMed
39.
Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17:5321–33.PubMed
40.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.PubMed
41.
Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788–92.PubMed
42.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–97.PubMed
43.
Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. PNAS 2005;0509714102.
44.
Sato N, Sakamaki K, Terada N, Arai K, Miyajima A. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 1993;12:4181–9.PubMed
45.
Evans GA, Goldsmith MA, Johnston JA, Xu W, Weiler SR, Erwin R, et al. Analysis of interleukin-2-dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin-2-dependent mitogenesis does not require Shc phosphorylation or receptor association. J Biol Chem 1995;270:28858–63.PubMed
46.
Fujii H, Nakagawa Y, Schindler U, Kawahara A, Mori H, Gouilleux F, et al. Activation of Stat5 by interleukin 2 requires a carboxyl- terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci 1995;92:5482–6.PubMed
47.
Terada K, Kaziro Y, Satoh T. Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3. J Biol Chem 1995;270:27880–6.PubMed
48.
Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN, Miura O. Physical and functional interactions between stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 1996;88:4415–25.PubMed
49.
Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopodis D, Weinstein Y, et al. Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 1996;16:1622–31.PubMed
50.
Zang HS, Sato K, Nakajima H, McKay C, Ney PA, Ihle JN. The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J 2001;20:3156–66.PubMed
51.
Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4:313–9.PubMed
52.
Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996;382:174–7.PubMed
53.
Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996;380:630–3.PubMed
54.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295–303.PubMed
55.
Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui ALF, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999;18:4754–65.PubMed
56.
Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src- transformed cell lines. Mol Cell Biol 1996;16:1595–603.PubMed
57.
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, et al. Signal transducer and activator of átranscription (STAT)5 activation by BCR/ABL is dependent on intact Src Homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999;189:1229–42.PubMed
58.
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, et al. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 1999;19:7519–28.PubMed
59.
Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, et al. Stat5 Is Essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000;6:693–704.PubMed
60.
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118–25.PubMed
61.
Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006;107:4898–906.PubMed
62.
Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol 2000;164:2533–41.PubMed
63.
Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999;19:4672–83.PubMed
64.
Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 to facilitate the activation of Cdk4/6 and early G1 phase progression. J Biol Chem 2002;277:31263–9.PubMed
65.
Martino A, Holmes JH IV, Lord JD, Moon JJ, Nelson BH. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 2001;166:1723–9.PubMed
66.
Friedrichsen BN, Richter HE, Hansen JA, Rhodes CJ, Nielsen JH, Billestrup N, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic {beta}-Cells. Mol Endocrinol 2003;17:945–58.PubMed
67.
Moon JJ, Rubio ED, Martino A, Krumm A, Nelson BH. A permissive role for phosphatidylinositol 3-kinase in the Stat5- mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem 2004;279:5520–7.PubMed
68.
Fernandez de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 2004;24:10058–71.
69.
Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667–79.PubMed
70.
Nagata Y, Moriguchi T, Nishida E, Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 1997;90:929–34.PubMed
71.
Nosaka Y, Arai A, Miyasaka N, Miura O. CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3. J Biol Chem 1999;274:30154–62.PubMed
72.
Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein-Oppenheimer C, et al. Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. Leukemia 2000;14:1060–79.PubMed
73.
Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M, et al. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. Leukemia 2000;14:1080–96.PubMed
74.
Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003;22:2478–92.PubMed
75.
Lavoie JN, L’Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608–16.PubMed
76.
Khaled AR, Bulavin DV, Kittipatarin C, Li WQ, Alvarez M, Kim K, et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 2005;169:755–63.PubMed
77.
Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655–7.PubMed
78.
Brazil DP, Park J, Hemmings BA. PKB binding proteins: getting in on the akt. Cell 2002;111:293–303.PubMed
79.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687–9.PubMed
80.
Craddock BL, Orchiston EA, Hinton HJ, Welham MJ. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling. J Biol Chem 1999;274:10633–40.PubMed
81.
Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499–511.PubMed
82.
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21(Cip1/WAF1) by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:438.
83.
Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27:462–7.PubMed
84.
Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002;250:1–23.PubMed
85.
Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000;20:9138–48.PubMed
86.
Stahl M, Dijkers PF, Kops GJPL, Lens SMA, Coffer PJ, Burgering BMT, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002;168:5024–31.PubMed
87.
Alvarez B, Martinez C, Burgering BMT, Carrera AC. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 2001;413:744–7.PubMed
88.
Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci 1997;94:11345–50.PubMed
89.
Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 1999;93:3757–73.PubMed
90.
Haseyama Y, Sawada K, Oda A, Koizumi K, Takano H, Tarumi T, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood 1999;94:1568–77.PubMed
91.
Mathieu AL, Gonin S, Leverrier Y, Blanquier B, Thomas J, Dantin C, et al. Activation of the phosphatidylinositol 3-kinase/Akt pathway protects against interleukin-3 starvation but not DNA damage-induced apoptosis. J Biol Chem 2001;276:10935–42.PubMed
92.
Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004;200:659–69.PubMed
93.
Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997;7:679–89.PubMed
94.
Brennan P, Babbage JW, Thomas G, Cantrell D. p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol 1999;19:4729–38.PubMed
95.
Mahmud DL, Amlak M, Deb DK, Platanias LC, Uddin S, Wickrema A. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene 2002;21:1556–62.PubMed
96.
Bouscary D, Pene F, Claessens YE, Muller O, Chretien S, Fontenay-Roupie M, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003;101:3436–43.PubMed
97.
Henry MK, Nimbalkar D, Hohl RJ, Quelle FW. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Exp Cell Res 2004;299:257–66.PubMed
98.
Fox BC, Crew TE, Welham MJ. Phosphoinositide 3-kinases can act independently of p27Kip1 to regulate optimal IL-3-dependent cell cycle progression and proliferation. Cell Signal 2005;17:473–87.PubMed
99.
Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25–31.PubMed
100.
Roberts JM, Sherr CJ. Bared essentials of CDK2 and cyclin E. Nat Genet 2003;35:9–10.PubMed
101.
Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233–45.PubMed
102.
Henry MK, Eapen AK, Quelle FW. PI-3 kinase signaling pathways activate cdk2 and override DNA damage-induced growth arrest in hematopoietic cells. Keystone Symposia—The Molecular Basis of Cancer 2001.
103.
Nimbalkar D, Henry MK, Quelle FW. Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res 2003;63:1034–9.PubMed
104.
Moon JJ, Nelson BH. Phosphatidylinositol 3-kinase potentiates, but does not trigger, T cell proliferation mediated by the IL-2 receptor. J Immunol 2001;167:2714–23.PubMed
105.
Henry MK, Lynch JT, Eapen AK, Quelle FW. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 2001;98:834–41.PubMed
Metadata
Title
Cytokine signaling to the cell cycle
Author
Frederick W. Quelle
Publication date
01-11-2007
Publisher
Humana Press Inc
Published in
Immunologic Research / Issue 1-3/2007
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-007-0080-5

Other articles of this Issue 1-3/2007

Immunologic Research 1-3/2007 Go to the issue

OriginalPaper

Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells

OriginalPaper

CD8 T cell memory development: CD4 T cell help is appreciated

OriginalPaper

The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens

OriginalPaper

Multiple roles of TRAF3 signaling in lymphocyte function

OriginalPaper

The isolator piglet: a model for studying the development of adaptive immunity

OriginalPaper

Modulation of NK cell activity by CpG oligodeoxynucleotides